APP Pharmaceuticals Inc

APP Pharmaceuticals — Abraxis BioScience — Debt Investor Presentation (November 2007)

54 slides from APP Pharmaceuticals's debt investor presentation, Nov 8, 2007

  1. Slide 1: APP Pharmaceuticals, Inc.

    Exhibit 99.2 APP Pharmaceuticals, Inc. APP Pharmaceuticals, Inc.

  2. Slide 2: Forward-Looking Statements

    1 1 FORWARD-LOOKING STATEMENTS The statements contained in this presentation that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this presentation include statements regardin

  3. Slide 3: Table of Contents

    2 2 Transaction Summary Company Snapshot Key Credit Highlights Company Overview Financial Overview: 2004 – LTM 9/30/2007E 2007 Projected Financials Management Biographies Table of Contents Transaction Summary Company Snapshot Key Credit Highlights Company Overview Financial Overview: 2004 – LTM 9/30

  4. Slide 4: Transaction Summary

    Transaction Summary Transaction Summary

  5. Slide 5: Transaction Description

    4 4 On July 2, 2007, Abraxis BioScience, Inc. ("Abraxis") announced that its board approved the separation of its proprietary business, Abraxis Oncology and Abraxis Research (the "New Abraxis BioScience"), from its hospital-based business, Abraxis Pharmaceutical Products ("New APP" or the "Company")

  6. Slide 6: Strategic Rationale

    5 5 Benefits: Enables each stand-alone publicly traded company to: Focus on respective pipelines Compete more effectively in each specialized marketplace Pursue unique strategic initiatives Allows valuation on pure-play metrics and accommodates different capital requirements Unlocking APP Value: APP

  7. Slide 7: Transaction Description

    6 6 The transaction will be structured as a spin-off of the New Abraxis BioScience Expected to be a tax-free transaction to Abraxis and its shareholders. On October 5, 2007, Abraxis received a private letter ruling from the Internal Revenue Service regarding the material United States federal income

  8. Slide 8: Company Snapshot

    Company Snapshot Company Snapshot

  9. Slide 9: Largest Pure-play US Stand-alone, Hospital-based Injectable Pharmaceuticals Company

    8 8 Approx. 1,400 employees 9/30/07E LTM Sales = $652 million 100+ marketed products 400+ dosage forms 60+ products in development 29 ANDAs pending 9/30/07E LTM Sales: $213M 55 marketed products #1 in the U.S. for 15 products #2 in the U.S. for 10 products Critical Care 9/30/07E LTM Sales: $54M 16 m

  10. Slide 10: New APP's Products Touch Every Aspect of the Hospital

    9 9 New APP’s Products Touch Every Aspect of the Hospital Operating Room Emergency Room Pediatrics Cardiac Care Psychiatrics OB/GYN Intensive Care Unit Orthopedics Dialysis Oncology

  11. Slide 11: Business Strategy

    10 10 Establish a broad product portfolio that comprehensively mirrors the U.S. hospital market demand Develop injectable products for which New APP is the exclusive manufacturer in the United States Develop difficult to manufacture products for which there is little or no competition Develop manufa

  12. Slide 12: APP's Key Advantages for Success

    APP’s Key Advantages for Success APP’s Key Advantages for Success

  13. Slide 13: Key Advantages for Success

    12 12 Higher Barriers to Entry for Generic Injectables than Solid Oral Products Increasing Volume of U.S. Injectable Patent Expirations Market Leading Generic Injectables Company Differentiated Product Portfolio with Unique Market Position One of the Most Diverse Injectable Portfolios #1 in Injectab

  14. Slide 14: Higher Barriers to Entry for Generic Injectables than Solid Oral Products

    13 13 Sterile manufacturing standards require special airflow and purification processes, and water for injection Separate manufacturing facilities required for certain products, including cephalosporins and penicillins, and separate manufacturing areas for cytotoxics More difficult API sourcing - s

  15. Slide 15: Increasing Volume of U.S. Injectable Patent Expirations

    14 14 $498 $1,529 $993 $850 $818 $3,006 $2,216 $1,194 $1,303 $1,143 $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 11 11 11 15 9 5 9 8 14 5 # of Products: Source: U.S. FDA Orange Book and APP estimates. Excludes biologics. 2006 IMS reported sales.

  16. Slide 16: Market Leading Generic Injectables Company

    15 15 (a) IMS 2007 1H annualized. (b) 2001 – 10/19/2007. $0 $200 $400 $600 $800 $1,000 $1,200 0 100 200 300 400 500 600 Dollar Sales Acquisition Unit Sales Mayne AZ Propofol #1 or #2 68% #3 18% >3 14% > 45 10 10 0 10 20 30 40 50 60 70 New APP 2001 - 2005 2006 2007 YTD 65 #1 in ANDA Approvals (b) Mar

  17. Slide 17: One of the Most Diverse Injectable Portfolios

    16 16 0% 20% 40% 60% 80% 100% Overall Market New APP Bedford Teva / Sicor Hospira / Mayne Baxter Sandoz Oncology Anti-infective Critical Care Anesthetics Note: Breakdown based on dollar sales. New APP includes AstraZeneca for the full year 2006. Source: IMS 2006 full year data One of the Most Divers

  18. Slide 18: #1 in Injectable ANDA Approvals from 2001 - 10/19/2007

    17 17 Note: Excludes tentative approvals. Source: CDER as of December 31, 2006 / FDA OGD Generic Approvals website as of 2007 YTD 45 45 30 30 8 10 7 9 8 5 8 6 6 3 60 45 44 22 16 19 2 1 10 65 0 10 20 30 40 50 60 70 New APP Bedford Teva / Sicor Hospira / Mayne Baxter Sandoz Cumulative 2001-2005 2006 A

  19. Slide 19: Strong Product Development Capabilities and Pipeline

    18 18 (a) Includes tentative approvals, YTD as of 10/19/2007. Source: Company information, 2006 IMS National Sales Perspective 12 26 29 14 (a) Feasibility Development/Stability FDA Pending Approvals $1.7bn $6.4bn $2.5bn 2006 Branded Sales: Number of Products: Strong Product Development Capabilities

  20. Slide 20: Manufacturing Capabilities Provide a Strategic Competitive Advantage

    19 19 Developed manufacturing capabilities that span the entire spectrum of delivery forms Over $130 million of capital invested over the past 5 years to boost manufacturing capacity and establish a platform to support future growth Modest future capital expenditures required Ability to manufacture

  21. Slide 21: Excellent GPO & Distribution Relationships

    20 20 Existing GPO contracts cover >95% of the acute care market Existing relationships extend to other channels (e.g., clinics, home care, surgi-center) Big 3 national wholesalers inventory 95%+ of APP dosage forms and distribute 80%+ of sales dollars Sole source contractual relationship with US On

  22. Slide 22: Impressive Record of Revenue Growth

    21 21 $137 $166 $192 $278 $351 $405 $385 $583 $652 0 100 200 300 400 500 600 700 1999 2000 2001 2002 2003 2004 2005 2006 LTM 23% revenue 7-year CAGR from 1999 to 2006 54% Gross margin in 2006 43% Adjusted EBITDA in 2006 Strong cash flow generation Note: LTM is as of 9/30/07E. 2006 includes only six

  23. Slide 23: Highly Experienced Management Team

    22 22 21 years in the industry 31 years in the industry 20 years IT experience 31 years in the industry 25 years in the industry 16 years in the industry Background : Pharmacia, Searle, Monsanto Background : Fujisawa, Ortho (division of J&J), Schering, Merck Background : Guidant Background : Cardina

  24. Slide 24: Company Overview

    Company Overview Company Overview

  25. Slide 25: An Integrated Injectables Business

    24 24 Manufacturing Quality Assurance/ Quality Control Product Development Regulatory Affairs Business Development Supply Chain Customer Service Sales & Marketing New APP An Integrated Injectables Business

  26. Slide 26: Product Overview

    Product Overview Product Overview

  27. Slide 27: Differentiated Therapeutic Mix With a Broad Portfolio in Each Category

    26 26 14 13 10 7 5 0 5 10 15 20 New APP Hospira / Mayne Baxter Sandoz Bedford Teva / Sicor Source: 2006 IMS (excludes systems) 46 38 37 21 11 0 9 18 27 36 45 Hospira / Mayne Bedford New APP Baxter Teva / Sicor Sandoz 22 18 14 8 0 5 10 15 20 25 Bedford Teva / Sicor New APP Hospira / Mayne Baxter Sand

  28. Slide 28: Anti-Infectives

    27 27 21 marketed anti-infective products (a) #1 in the U.S. for 8 products (b) 28% CAGR since 1999 12 ANDAs pending and 7 in development $36 $44 $52 $71 $89 $122 $165 $206 $183 $0 $40 $80 $120 $160 $200 $240 1999 2000 2001 2002 2003 2004 2005 2006 LTM Note: LTM figures are as of 9/30/07E and contai

  29. Slide 29: Anesthetics and Analgesics: Demonstrated Ability to Leverage Infrastructure for Acquisitions

    28 28 Acquired 8 marketed anesthetic / analgesic products in over 100 dosages and formulations from AstraZeneca in June 2006 5-year supply agreement Right of first offer to license Naropin and Diprivan ex- U.S. Right of first negotiation for authorized generic injectables in U.S. Diprivan and Naropi

  30. Slide 30: Critical Care

    29 29 60 marketed injectable critical care products (a) #1 in the U.S. for 15 products (b) #2 in the U.S. for 10 products (b) 15% CAGR since 1999 8 ANDAs pending and 19 in development $75 $73 $92 $119 $149 $164 $155 $202 $213 $0 $50 $100 $150 $200 $250 1999 2000 2001 2002 2003 2004 2005 2006 LTM Not

  31. Slide 31: Oncology

    30 30 16 marketed injectable products in 33 dosages and formulations #1 in the U.S. for 5 products (a) 23% CAGR since 1999 9 ANDAs pending and 12 in development $13 $37 $31 $61 $81 $96 $52 $57 $54 $0 $30 $60 $90 $120 1999 2000 2001 2002 2003 2004 2005 2006 LTM Note: LTM figures are as of 9/30/07E an

  32. Slide 32: Pipeline overview

    Pipeline overview Pipeline overview

  33. Slide 33: Industry Leading Product Development Organization

    32 32 Robust ANDA pipeline currently pending FDA approval Highly educated and experienced management team and scientists Over 50% of staff hold advanced degrees (26 people) Over 50% of staff have over 10 years experience (26 people) 20% have over 20 years experience (11 people) Educational backgroun

  34. Slide 34: Pipeline Development Cycle

    33 33 3-6 months 12-18 months 10-15 months Feasibility (Financial) Development / Stability (Scientific) Market assessment Financial analysis Patent clearance API identified and / or in testing Early lab experimentation Project approved for development Project team formed Full development activities

  35. Slide 35: Growth in New Product Development

    34 34 3 10 14 14 20 23 30 0 5 10 15 20 25 30 2000 2001 2002 2003 2004 2005 2006 # of ANDA Submissions 10 10 10 13 14 11 # of ANDA Approvals 10 12 5 12 6 10 Growth in New Product Development ANDAs Pending at FDA at End of Year

  36. Slide 36: Manufacturing Overview

    Manufacturing Overview Manufacturing Overview

  37. Slide 37: Manufacturing Capabilities Provide a Strategic Competitive Advantage

    36 36 Comprehensive and diverse injectable manufacturing capabilities include: Glass and plastic vials Sterile powders Liquids Lyophilized Aseptic Terminally sterilized Syringes Manufacturing Capabilities Provide a Strategic Competitive Advantage Comprehensive and diverse injectable manufacturing ca

  38. Slide 38: Manufacturing Facilities

    37 37 Grand Island, NY Manufacturing Facility Grand Island, NY Cephalosporin Facility Melrose Park, IL Manufacturing Facility (1) 342,000 sq. ft. (includes all facilities) Current capacity 160 million annual units Aseptic vial filings Terminal sterilization Dedicated cephalosporin manufacturing 6 ly

  39. Slide 39: Puerto Rico Manufacturing Facility

    38 38 272,000 sq. ft. manufacturing facility (including 90,000 sq. ft. leased back to Pfizer which will be conveyed to New Abraxis BioScience) 51,600 sq. ft. QA & Labs Current annual capacity: 42mm units U.S. & E.U. compliant facilities Aseptic vial filling 2 lyophilizers Metered dosed inhalers Full

  40. Slide 40: Manufacturing Summary

    39 39 Four U.S. and E.U. approved facilities Highly automated state-of-the-art manufacturing lines designed to: Minimize standard cost Deliver consistent high quality products Dual site manufacturing capability for key products to: Protect market share React to market opportunities Planned capacity

  41. Slide 41: Transaction Transition and Separation Plan

    Transaction Transition and Separation Plan Transaction Transition and Separation Plan

  42. Slide 42: Transition Plan Overview

    41 41 New APP and New Abraxis BioScience will provide the other party with various services on an interim, transitional basis generally for up to 24 months, and 4 or 5 years in the case of manufacturing related activities Payments will be based on actual costs for each service New Abraxis BioScience

  43. Slide 43: Financial Overview: 2004 – LTM 9/30/07E

    Financial Overview: 2004 – LTM 9/30/07E Financial Overview: 2004 – LTM 9/30/07E

  44. Slide 44: Basis of Presentation of Financials

    43 43 The unaudited Summary Income Statement and Quarterly Analysis of New APP were derived from the elimination of the historical results of operations of the business of New Abraxis BioScience, as reflected in the Form 10 Registration Statement of New Abraxis Inc. filed with the SEC on November 2,

  45. Slide 45: Summary Income Statement

    44 44 ($ mm) Estimated Year ending December 31, Nine months ended Six months ended LTM ($mm) 2004 2005 2006 9/30/06 E 6/30/07 Q3 07E 9/30/07 E Revenue Anti-Infective $122.0 $164.7 $206.1 $152.0 $87.1 $41.3 $182.5 Anesthetic / Analgesic 17.3 14.8 118.5 50.8 87.1 47.1 201.9 Critical Care 164.0 154.6 2

  46. Slide 46: Derived EBITDA Calculations

    45 45 DERIVED EBITDA CALCULATIONS (unaudited, in thousands, except per share amounts) New Abraxis APP New Abraxis APP New Abraxis APP EBITDA CALCULATION: 10K Data Form 10 Data Adjustment(1) Derived 10K Data Form 10 Data Adjustment(1) Derived 10K Data Form 10 Data Adjustment(1) Derived Net income/(lo

  47. Slide 47: Derived EBITDA Calculations (10Q Data)

    46 46 New Abraxis APP New Abraxis APP New Abraxis APP EBITDA CALCULATION: 10Q Data Form 10 Data Adjustment(1) Derived 10Q Data Form 10 Data Adjustment(1) Derived 10Q Data Form 10 Data Adjustment(1) Derived Net income/(loss) 11,115 $ (5,671) $ (552) $ 17,338 $ 23,086 $ (14,534) $ 12,447 $ 25,173 $ 34

  48. Slide 48: 2007 Projected Financials

    2007 Projected Financials 2007 Projected Financials

  49. Slide 49: Quarterly Analysis

    48 48 ($ mm) 2006 By Quarter 2007 By Quarter Q1A Q2A Q3A Q4A Total Q1A Q2A Q3E Q4E Total Core Products $113.6 $120.0 $108.9 $136.9 $479.5 Revenue $96.2 $123.3 $109.0 $133.0 $461.4 24% 25% 23% 29% 100% % of core products sales 21% 27% 24% 29% 100% Acquired AA Products $41.0 $62.8 $103.7 Revenue $44.1

  50. Slide 50: Management Biographies

    Management Biographies

  51. Slide 51: Patrick Soon-Shiong, M.D.

    50 50 Served as Chief Executive Officer (CEO) of Abraxis BioScience since December 2005 and as Executive Chairman since November 2004 Previously served as the CEO and Chairman of the Board of Directors since inception in March 1996 to November 2004 and as President from July 2001 to November 2004 Fr

  52. Slide 52: Tom Silberg

    51 51 President of Abraxis Pharmaceutical Products (New APP) in September 2006, after joining Abraxis as Executive Vice President of Commercial Operations and Operational Excellence in May 2006. Mr. Silberg is responsible for all global operations for the New APP Most recently, Mr. Silberg served as

  53. Slide 53: Frank Harmon

    52 52 Chief Operating Officer and Executive Vice President of Abraxis Pharmaceutical Products (New APP) in September 2006, after having joined Abraxis in May 2006 as the Executive Vice President of Global Operations Mr. Harmon oversees global manufacturing operations; corporate quality assurance and

  54. Slide 54: Lisa Gopala

    53 53 Joined the company in July 2006 and was officially appointed Chief Financial Officer of Abraxis BioScience on August 10, 2006 Ms. Gopala oversees and manages all financial aspects of the company, including accounting, strategic planning and analysis, treasury and tax Before joining Abraxis, Ms

Abraxis BioScience — Debt Investor Presentation (November 2007) on 6ix